Sustaining Tissue Resident Memory T cells
维持组织驻留记忆 T 细胞
基本信息
- 批准号:10544791
- 负责人:
- 金额:$ 52.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAntigen-Presenting CellsAntigensAntitumor ResponseAutoantigensAutoimmunityBloodCD8-Positive T-LymphocytesCD8B1 geneCXCR6 geneCancer RemissionCell MaintenanceCell physiologyCellsDataDendritic CellsDependenceDermisDisease-Free SurvivalExcisionFutureGenerationsGenetic TranscriptionGrowthHair follicle structureITGAX geneImageImmune checkpoint inhibitorImmune responseImmunityImmunologic MemoryImmunotherapyInfectionInflammationInvadedKnock-outLaboratoriesLocationLongevityLymph Node Subcapsular SinusLymph Node TissueLymphoidMaintenanceMalignant NeoplasmsMemoryModelingMolecularMusMyeloid CellsNeoplasm MetastasisOperative Surgical ProceduresPatientsPopulationPositioning AttributeRecurrent tumorReportingRoleSentinelSignal TransductionSiteSkinSkin TissueSurvivorsT memory cellT-Cell ReceptorT-LymphocyteTestingTissuesTranscriptTumor Cell InvasionTumor ImmunityTumor TissueVirus DiseasesVitiligoWorkanti-melanoma immunitychemokinedraining lymph nodelymph nodesmelanomamemory recallmemory retentionmouse modelnovelreceptorresidenceresponsetissue resident memory T celltumortumor growth
项目摘要
ABSTRACT
Durable immunity to cancer is sustained by memory T cells. In contrast to circulating memory subsets, which
traffic in and out of the blood, tissue-resident memory (TRM) cells are transcriptionally programed for prolonged
residence and recall function within tissue. Collaborative studies between our laboratories were among the first
to identify a requirement for TRM cells in immunity to cancer. Using a melanoma-associated vitiligo (MAV) mouse
model that closely mimics the vitiligo that develops in immune checkpoint inhibitor-treated melanoma patients
who benefit from prolonged disease-free survival, we showed that skin TRM cells are necessary and sufficient for
long term protective immunity against melanoma in the dermis. However, mechanisms for controlling TRM cell
persistence and identity as well as the contribution of TRM cells to tumor immunity at sites of frequent metastasis
remain unclear. In this application, we examine an unexpected mechanism for TRM cell maintenance in the skin
and reveal a new subset of vitally important TRM cells that persist in tumor-draining lymph nodes.
In the skin of mice with MAV, as well as melanoma patients with vitiligo, immunofluorescent imaging revealed
that TRM cells form lymphoid aggregates containing large populations of CD11c-expressing myeloid cells. While
prior work indicates that CD11c+ dendritic cells (DCs) are critical for initiating immune responses but dispensable
for reactivating TRM we find that depletion of CD11c-expressing cells results in rapid disaggregation and loss of
CD8 TRM cells in the skin. We further show that the CXCR6/CXCL16 axis is required for TRM cell persistence and
tumor protection in the skin. These findings identify a critical requirement for CXCL16-expressing myeloid cells
in coordinating the organization and retention of CXCR6-expressing TRM in the tissue, which will be examined in
Specific Aim 1. The importance of the CXCR6/CXCL16 axis and persisting self antigen in controlling TRM cell
function and plasticity will be tested in Specific Aim 2. Finally, parallel mechanisms will be explored in lymph
nodes (LNs) where our preliminary studies led us to discover a novel population of tumor-specific T cells that is
crucial for protection against melanoma growth in lymph nodes. The presence of LN TRM cells has not previously
been shown in the setting of cancer. A role for APCs and chemokines in maintaining such responses is
essentially unknown, and will be the focus of Specific Aim 3. This proposal will thus test the overarching
hypothesis that tumor-specific TRM cells— both in skin and draining lymph nodes—rely on key interactions with
APCs and chemokines for their proper positioning, maintenance, and anti-tumor function.
摘要
对癌症的持久免疫力是由记忆T细胞维持的。与循环存储子集相反,循环存储子集
进出血液的交通,组织驻留记忆(TRM)细胞被转录编程,以延长
在组织内的驻留和回忆功能。我们实验室之间的合作研究是第一批
确定TRM细胞在抗癌免疫中的需求。使用黑色素瘤相关性白癜风(MAV)小鼠
与免疫检查点抑制剂治疗的黑色素瘤患者发生白癜风非常相似的模型
谁受益于延长的无病生存,我们表明皮肤TRM细胞是必要的和充分的
针对真皮黑色素瘤的长期保护性免疫。然而,控制TRM细胞的机制
TRM细胞在肿瘤频繁转移部位的持久性和同一性及其在肿瘤免疫中的作用
目前仍不清楚。在这个应用中,我们研究了皮肤中TRM细胞维持的一种意想不到的机制
并揭示了一个新的至关重要的TRM细胞亚群,这些细胞持续存在于肿瘤引流的淋巴结中。
免疫荧光成像显示,感染MAV的小鼠以及患有白癜风的黑色素瘤患者的皮肤
TRM细胞形成的淋巴聚集体包含大量表达CD11c的髓系细胞。而当
先前的工作表明,CD11c+树突状细胞(DC)对于启动免疫反应是关键的,但却是必不可少的
为了重新激活TRM,我们发现CD11c表达细胞的耗尽会导致快速解聚和丢失
皮肤中的CD8TRM细胞。我们进一步证明CXCR6/CXCL16轴是TRM细胞持续存在所必需的,并且
皮肤中的肿瘤保护。这些发现确定了表达CXCL16的髓系细胞的关键要求
在协调组织中表达CXCR6的TRM的组织和保留方面,这将在
特定目的1.CXCR6/CXCL16轴和持续自身抗原在控制TRM细胞中的重要性
功能和可塑性将在特定的目标2中进行测试。最后,将在淋巴中探索并行机制
结节(LN),我们的初步研究使我们发现了一种新的肿瘤特异性T细胞群体,即
对防止淋巴结黑色素瘤生长至关重要。LN TRM细胞的存在以前没有
在癌症的背景下被展示出来。APC和趋化因子在维持这种反应中的作用是
基本上是未知的,并将成为具体目标3的重点。因此,这项提议将考验总体目标
假设肿瘤特异性TRM细胞--包括皮肤和引流淋巴结中的--依赖于与
APC和趋化因子用于其正确的定位、维持和抗肿瘤功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yina Hsing Huang其他文献
Yina Hsing Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yina Hsing Huang', 18)}}的其他基金
Activating Native Tumor Immunity with IL-33 Armored CARs
使用 IL-33 装甲 CAR 激活天然肿瘤免疫
- 批准号:
10744438 - 财政年份:2023
- 资助金额:
$ 52.68万 - 项目类别:
Directing Cytokine Specificity Through Co-translational Carrier Coupling
通过共翻译载体偶联指导细胞因子特异性
- 批准号:
10581947 - 财政年份:2022
- 资助金额:
$ 52.68万 - 项目类别:
PIP3-INDEPENDENT REGULATION OF AKT1 ACTIVITY IN T CELLS
T 细胞中 AKT1 活性的 PIP3 独立调节
- 批准号:
8225208 - 财政年份:2011
- 资助金额:
$ 52.68万 - 项目类别:
PIP3-INDEPENDENT REGULATION OF AKT1 ACTIVITY IN T CELLS
T 细胞中 AKT1 活性的 PIP3 独立调节
- 批准号:
8788798 - 财政年份:2011
- 资助金额:
$ 52.68万 - 项目类别:
Novel Requirements for Akt1 in T Cell Commitment
T 细胞承诺中对 Akt1 的新要求
- 批准号:
9405831 - 财政年份:2011
- 资助金额:
$ 52.68万 - 项目类别:
Novel Requirements for Akt1 in T Cell Commitment
T 细胞承诺中对 Akt1 的新要求
- 批准号:
9246741 - 财政年份:2011
- 资助金额:
$ 52.68万 - 项目类别:
Novel Requirements for Akt1 in T Cell Commitment
T 细胞承诺中对 Akt1 的新要求
- 批准号:
10077817 - 财政年份:2011
- 资助金额:
$ 52.68万 - 项目类别:
相似海外基金
Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
- 批准号:
10751133 - 财政年份:2023
- 资助金额:
$ 52.68万 - 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
- 批准号:
10696138 - 财政年份:2022
- 资助金额:
$ 52.68万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10663066 - 财政年份:2022
- 资助金额:
$ 52.68万 - 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
- 批准号:
10537159 - 财政年份:2022
- 资助金额:
$ 52.68万 - 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
- 批准号:
21K08723 - 财政年份:2021
- 资助金额:
$ 52.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10156950 - 财政年份:2021
- 资助金额:
$ 52.68万 - 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
- 批准号:
10631854 - 财政年份:2021
- 资助金额:
$ 52.68万 - 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
- 批准号:
10153927 - 财政年份:2021
- 资助金额:
$ 52.68万 - 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
- 批准号:
10331830 - 财政年份:2021
- 资助金额:
$ 52.68万 - 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
- 批准号:
20K16294 - 财政年份:2020
- 资助金额:
$ 52.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists